Heart & blood pressure · Kansas City area, MO
Heart and blood pressure studies in Kansas City area, MO
41 recruiting studies have a site in the Kansas City area. This page includes nearby cities such as Independence, Lee's Summit, North Kansas City, Liberty.
41 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Kansas City, MO + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1
Liver Adiposity Effects on Pediatric Statin
Children's Mercy Hospital Kansas City
- Location
- Kansas City, MO
- Eligibility basics
- Ages 8–21
- Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics
- Location
- Kansas City, MO + 64 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Prevail Global Study
Medtronic Vascular
- Location
- Kansas City, MO + 53 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
AstraZeneca
- Location
- Columbia, MO + 151 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Novo Nordisk A/S
- Location
- Kansas City, MO + 58 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)
Affinia Therapeutics
- Location
- Kansas City, MO + 3 other US sites
- Eligibility basics
- Ages 18–70
- Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
Boston Scientific Corporation
- Location
- Kansas City, MO + 46 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
- Location
- St Louis, MO + 40 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)
Medtronic Cardiac Ablation Solutions
- Location
- Kansas City, MO + 20 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
NORM-HF Pivotal Study
Foundry Innovation & Research 1, Limited (FIRE1)
- Location
- Kansas City, MO + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Boehringer Ingelheim
- Location
- North Kansas City, MO + 91 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Boehringer Ingelheim
- Location
- Kansas City, MO + 78 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Gossamer Bio USA, Inc.
- Location
- St Louis, MO + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
AstraZeneca
- Location
- Columbia, MO + 93 other US sites
- Eligibility basics
- Ages 18–130
- RecruitingPhase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Cytokinetics
- Location
- Kansas City, MO + 80 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
Reprieve Cardiovascular, Inc
- Location
- St Louis, MO + 33 other US sites
- Eligibility basics
- Ages 22+
- Recruiting
ELEVATE High-Risk PCI Pivotal Study
Magenta Medical Ltd.
- Location
- Kansas City, MO + 32 other US sites
- Eligibility basics
- Ages 18–88
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- City of Saint Peters, MO + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 2/Phase 3
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Kardigan, Inc.
- Location
- Kansas City, MO + 26 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
ELEVATE-HFpEF Clinical Study
Medtronic Cardiac Rhythm and Heart Failure
- Location
- Kansas City, MO + 25 other US sites
- Eligibility basics
- Ages 40+
- Recruiting
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Shockwave Medical, Inc.
- Location
- Kansas City, MO + 66 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
35Pharma Inc
- Location
- Kansas City, MO + 1 other US site
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
AstraZeneca
- Location
- Kansas City, MO + 104 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.